Cargando…

Impact of age and comorbidities on health-related quality of life for patients with prostate cancer: evaluation before a curative treatment

BACKGROUND: Interpretation of comparative health-related quality of life (HRQOL) studies following different prostate cancer treatments is often difficult due to differing patient ages. Furthermore, age-related changes can hardly be discriminated from therapy-related changes. The evaluation of age-a...

Descripción completa

Detalles Bibliográficos
Autores principales: Pinkawa, Michael, Fischedick, Karin, Gagel, Bernd, Piroth, Marc D, Asadpour, Branka, Klotz, Jens, Borchers, Holger, Jakse, Gerhard, Eble, Michael J
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2739535/
https://www.ncbi.nlm.nih.gov/pubmed/19703300
http://dx.doi.org/10.1186/1471-2407-9-296
_version_ 1782171604992655360
author Pinkawa, Michael
Fischedick, Karin
Gagel, Bernd
Piroth, Marc D
Asadpour, Branka
Klotz, Jens
Borchers, Holger
Jakse, Gerhard
Eble, Michael J
author_facet Pinkawa, Michael
Fischedick, Karin
Gagel, Bernd
Piroth, Marc D
Asadpour, Branka
Klotz, Jens
Borchers, Holger
Jakse, Gerhard
Eble, Michael J
author_sort Pinkawa, Michael
collection PubMed
description BACKGROUND: Interpretation of comparative health-related quality of life (HRQOL) studies following different prostate cancer treatments is often difficult due to differing patient ages. Furthermore, age-related changes can hardly be discriminated from therapy-related changes. The evaluation of age-and comorbidity-related changes was in focus of this study. METHODS: HRQOL of 528 prostate cancer patients was analysed using a validated questionnaire (Expanded Prostate Cancer Index Composite) before a curative treatment. Patients were divided into age groups ≤65, 66-70, 71-75 and >75 years. The impact of specific comorbidities and the Charlson Comorbidity Index (CCI) were evaluated. The questionnaire comprises 50 items concerning the urinary, bowel, sexual and hormonal domains for function and bother. For assessment of sexual and hormonal domains, only patients without prior hormonal treatment were included (n = 336). RESULTS: Urinary incontinence was observed increasingly with higher age (mean function scores of 92/88/85/87 for patients ≤65, 66-70, 71-75 and >75 years) - complete urinary control in 78%/72%/64%/58% (p < 0.01). Sexual function scores decreased particularly (48/43/35/30), with erections sufficient for intercourse in 68%/50%/36%/32% (p < 0.01) - a decrease of more than a third comparing patients ≤65 vs. 66-70 (36%) and 66-70 vs. 71-75 years (39%). The percentage of patients with comorbidities was lowest in the youngest group (48% vs. 66%/68%/63% for ages 66-70/71-75/>75 years; p < 0.05). A multivariate analysis revealed an independent influence of both age and comorbidities on urinary incontinence, specifically diabetes on urinary bother, and both age and diabetes on sexual function/bother. Rectal domain scores were not significantly influenced by age or comorbidities. A CCI>5 particularly predisposed for lower urinary and sexual HRQOL scores. CONCLUSION: Urinary continence and sexual function are the crucial HRQOL domains with age-related and independently comorbidity-related decreasing scores. The results need to be considered for the interpretation of comparative studies or longitudinal changes after a curative treatment.
format Text
id pubmed-2739535
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-27395352009-09-09 Impact of age and comorbidities on health-related quality of life for patients with prostate cancer: evaluation before a curative treatment Pinkawa, Michael Fischedick, Karin Gagel, Bernd Piroth, Marc D Asadpour, Branka Klotz, Jens Borchers, Holger Jakse, Gerhard Eble, Michael J BMC Cancer Research Article BACKGROUND: Interpretation of comparative health-related quality of life (HRQOL) studies following different prostate cancer treatments is often difficult due to differing patient ages. Furthermore, age-related changes can hardly be discriminated from therapy-related changes. The evaluation of age-and comorbidity-related changes was in focus of this study. METHODS: HRQOL of 528 prostate cancer patients was analysed using a validated questionnaire (Expanded Prostate Cancer Index Composite) before a curative treatment. Patients were divided into age groups ≤65, 66-70, 71-75 and >75 years. The impact of specific comorbidities and the Charlson Comorbidity Index (CCI) were evaluated. The questionnaire comprises 50 items concerning the urinary, bowel, sexual and hormonal domains for function and bother. For assessment of sexual and hormonal domains, only patients without prior hormonal treatment were included (n = 336). RESULTS: Urinary incontinence was observed increasingly with higher age (mean function scores of 92/88/85/87 for patients ≤65, 66-70, 71-75 and >75 years) - complete urinary control in 78%/72%/64%/58% (p < 0.01). Sexual function scores decreased particularly (48/43/35/30), with erections sufficient for intercourse in 68%/50%/36%/32% (p < 0.01) - a decrease of more than a third comparing patients ≤65 vs. 66-70 (36%) and 66-70 vs. 71-75 years (39%). The percentage of patients with comorbidities was lowest in the youngest group (48% vs. 66%/68%/63% for ages 66-70/71-75/>75 years; p < 0.05). A multivariate analysis revealed an independent influence of both age and comorbidities on urinary incontinence, specifically diabetes on urinary bother, and both age and diabetes on sexual function/bother. Rectal domain scores were not significantly influenced by age or comorbidities. A CCI>5 particularly predisposed for lower urinary and sexual HRQOL scores. CONCLUSION: Urinary continence and sexual function are the crucial HRQOL domains with age-related and independently comorbidity-related decreasing scores. The results need to be considered for the interpretation of comparative studies or longitudinal changes after a curative treatment. BioMed Central 2009-08-24 /pmc/articles/PMC2739535/ /pubmed/19703300 http://dx.doi.org/10.1186/1471-2407-9-296 Text en Copyright ©2009 Pinkawa et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Pinkawa, Michael
Fischedick, Karin
Gagel, Bernd
Piroth, Marc D
Asadpour, Branka
Klotz, Jens
Borchers, Holger
Jakse, Gerhard
Eble, Michael J
Impact of age and comorbidities on health-related quality of life for patients with prostate cancer: evaluation before a curative treatment
title Impact of age and comorbidities on health-related quality of life for patients with prostate cancer: evaluation before a curative treatment
title_full Impact of age and comorbidities on health-related quality of life for patients with prostate cancer: evaluation before a curative treatment
title_fullStr Impact of age and comorbidities on health-related quality of life for patients with prostate cancer: evaluation before a curative treatment
title_full_unstemmed Impact of age and comorbidities on health-related quality of life for patients with prostate cancer: evaluation before a curative treatment
title_short Impact of age and comorbidities on health-related quality of life for patients with prostate cancer: evaluation before a curative treatment
title_sort impact of age and comorbidities on health-related quality of life for patients with prostate cancer: evaluation before a curative treatment
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2739535/
https://www.ncbi.nlm.nih.gov/pubmed/19703300
http://dx.doi.org/10.1186/1471-2407-9-296
work_keys_str_mv AT pinkawamichael impactofageandcomorbiditiesonhealthrelatedqualityoflifeforpatientswithprostatecancerevaluationbeforeacurativetreatment
AT fischedickkarin impactofageandcomorbiditiesonhealthrelatedqualityoflifeforpatientswithprostatecancerevaluationbeforeacurativetreatment
AT gagelbernd impactofageandcomorbiditiesonhealthrelatedqualityoflifeforpatientswithprostatecancerevaluationbeforeacurativetreatment
AT pirothmarcd impactofageandcomorbiditiesonhealthrelatedqualityoflifeforpatientswithprostatecancerevaluationbeforeacurativetreatment
AT asadpourbranka impactofageandcomorbiditiesonhealthrelatedqualityoflifeforpatientswithprostatecancerevaluationbeforeacurativetreatment
AT klotzjens impactofageandcomorbiditiesonhealthrelatedqualityoflifeforpatientswithprostatecancerevaluationbeforeacurativetreatment
AT borchersholger impactofageandcomorbiditiesonhealthrelatedqualityoflifeforpatientswithprostatecancerevaluationbeforeacurativetreatment
AT jaksegerhard impactofageandcomorbiditiesonhealthrelatedqualityoflifeforpatientswithprostatecancerevaluationbeforeacurativetreatment
AT eblemichaelj impactofageandcomorbiditiesonhealthrelatedqualityoflifeforpatientswithprostatecancerevaluationbeforeacurativetreatment